Docoh
Loading...

VALN Valneva SE

News

From Benzinga Pro
48 Biggest Movers From Yesterday
21 Jan 22
News, Penny Stocks, Short Sellers, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
12 Health Care Stocks Moving In Thursday's Intraday Session
20 Jan 22
Intraday Update, Markets, Movers
38 Stocks Moving In Thursday's Mid-Day Session
20 Jan 22
News, Penny Stocks, Short Sellers, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 29.8% to $0.2550. Baudax Bio, last month, announced a $4.2 million registered direct offering.
Mid-Morning Market Update: Markets Open Higher; American Airlines Posts Narrower-Than-Expected Loss
20 Jan 22
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Following the market opening Thursday, the Dow traded up 0.92% to 35,352.17 while the NASDAQ rose 1.61% to 14,570.49. The S&P also rose, gaining, 1.06% to 4,581.00.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
20 Jan 22
Pre-Market Outlook, Markets, Movers
21 Stocks Moving in Thursday's Pre-Market Session
20 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 36.2% to $0.2675 in pre-market trading. Baudax Bio, last month, announced a $4.2 million registered direct offering.
52 Biggest Movers From Yesterday
20 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion.
12 Health Care Stocks Moving In Wednesday's After-Market Session
19 Jan 22
Movers
Gainers Acorda Therapeutics (NASDAQ:ACOR) stock rose 6.7% to $1.92 during Wednesday's after-market session. The company's market cap stands at $21.5 million.
Why Valneva Shares Are Soaring Today
19 Jan 22
News, Movers, Trading Ideas
Valneva SE (NASDAQ: VALN) is trading significantly higher Wednesday following results from an initial laboratory study, which demonstrated that serum antibodies induced by three doses of Valneva's COVID-19 vaccine candidate, VLA2001, neutralize the omicron variant.
Three doses of Valneva's COVID-19 Vaccine Neutralizes Omicron Variant, Lab Study Shows
19 Jan 22
Biotech, Long Ideas, News, Health Care, Small Cap, Movers, Trading Ideas, General
Valneva SE (NASDAQ: VALN) has announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva's COVID-19 vaccine candidate, VLA2001,
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
19 Jan 22
Pre-Market Outlook, Markets, Movers
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales
6 Jan 22
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Valneva Confirmed Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001
6 Jan 22
News, Small Cap
Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
45 Biggest Movers From Yesterday
5 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55.
12 Health Care Stocks Moving In Tuesday's Intraday Session
4 Jan 22
Movers
34 Stocks Moving In Tuesday's Mid-Day Session
4 Jan 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) jumped 31.7% to $0.5185 after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
4 Jan 22
Pre-Market Outlook, Markets, Movers
23 Stocks Moving in Tuesday's Pre-Market Session
4 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 62.1% to $1.05 in pre-market trading as the company issued a clinical and corporate update.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
30 Dec 21
Pre-Market Outlook, Markets, Movers
Valneva Posts Positive Lot-to-Lot Consistency Data For Its Single-Dose Chikungunya Vaccine
22 Dec 21
Biotech, News, Health Care, General
Valneva SE (NASDAQ: VALN)

Press releases

From Benzinga Pro
Valneva's Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant
19 Jan 22
Press Releases, General
Preliminary laboratory studies demonstrate that three doses of Valneva's inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant (B.1.1.529 lineage) 100% of tested serum samples
Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001
6 Jan 22
Press Releases, General
Saint Herblain (France), January 6, 2022 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its
Valneva and Scottish Enterprise in Advanced Discussions for Major Grant to Complete Livingston Site
23 Dec 21
News, Contracts, Press Releases
Saint Herblain (France), December 23, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it is in advanced discussions, with Scottish Enterprise, for a multi-million pound grant
Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate
21 Dec 21
Press Releases, General
Saint Herblain (France), December 21, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced positive topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya
Valneva Announces Positive Homologous Booster Data for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
16 Dec 21
Press Releases, General
Initial results show excellent immune response after third dose of VLA2001 administered 7 to 8 months after the second dose of primary vaccinationAntibody titers increased 42- to 106-fold two weeks after booster dose vs
Valneva Signs Advance Purchase Agreement with Bahrain for Inactivated COVID-19 Vaccine VLA2001
8 Dec 21
News, Contracts, Press Releases
Saint-Herblain (France), December 8, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced the signing of an advance purchase agreement with the Kingdom of Bahrain for the supply of one
Valneva Comments on COV-Boost Clinical Trial Data
3 Dec 21
Press Releases, General
Saint Herblain (France), December 3, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today responded to data published from the COV-Boost COVID-19 vaccine trial, which investigated the
Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001
2 Dec 21
Press Releases, General
Saint-Herblain (France), December 2, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today confirmed that the European Medicines Agency (EMA) has started a rolling review of VLA2001, its
Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001
29 Nov 21
News, Contracts, Press Releases
Saint-Herblain (France) and Dessau-Roßlau (Germany), November 29, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, and IDT Biologika today announced their collaboration for the production of
Valneva Signs Purchase Agreement with European Commission for its Inactivated COVID-19 Vaccine VLA2001
23 Nov 21
News, Contracts, Press Releases
Saint-Herblain (France), November 23, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that it has signed an Advance Purchase Agreement (APA) with the European Commission (EC) to
Valneva Reports Nine-Month 2021 Revenue and Cash
18 Nov 21
News, Press Releases
Strong financial position Cash and cash equivalents of €247.9 million at the end of September 2021 Reflects $107.6 million of gross proceeds raised in a US IPO and placement in Europe in the second quarter of 2021Does
Valneva to Present its Chikungunya Vaccine Candidate at the ASTMH 2021 Annual Meeting
15 Nov 21
Press Releases, General
Saint-Herblain (France), November 15, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced it will present its Chikungunya vaccine candidate, VLA1553, on November 18 and 19, 2021
Valneva Announces European Commission Approval of Advance Purchase Agreement for up to 60 Million Doses of Inactivated COVID-19 Vaccine VLA2001
10 Nov 21
News, Contracts, Press Releases
Saint-Herblain (France), November 10, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Commission ("EC") has approved an agreement pursuant to which Valneva would
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
8 Nov 21
Press Releases
Saint-Herblain (France), November 8, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional
Valneva Announces Closing of Approximately $102.0 Million Global Offering
3 Nov 21
Press Releases
Saint-Herblain (France), November 3, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA) (the "Company"), a specialty vaccine company, announced today the closing which occurred on November 2, 2021 of its previously announced
Valneva Announces the Pricing of its Global Offering of American Depositary Shares and Ordinary Shares
29 Oct 21
News, Press Releases
Saint-Herblain (France), October 29, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA) (the "Company"), a specialty vaccine company, announced today the pricing of 4,500,000 ordinary shares in a global offering to specified
Valneva Publishes Amendment to 2020 Universal Registration Document
26 Oct 21
Press Releases
Saint Herblain (France), October 27, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced the publication of an amendment filed with the French Financial Markets Authority ("AMF") on
Valneva Announces Launch of Proposed Global Offering of American Depository Shares and Ordinary Shares
26 Oct 21
Press Releases
Saint Herblain (France), October 26, 2021 – Valneva SE (NASDAQ:VALN, PARIS:VLA) (the "Company"), a specialty vaccine company, today announced its intention to issue and sell, subject to market conditions, 5,500,000 of